CD117在急性白血病中的表达及临床意义

Expression of CD117 in acute leukemia and its clinical significanc

目的探讨CD117在急性白血病中的表达及其临床意义。方法应用CD45/SSC设门,直接荧光标记法,经流式细胞术对73例急性髓系白血病(AML)和47例急性淋巴细胞白血病(ALL)进行CD117的检测。结果对照组、ALL及AML3组CD117的表达阳性率差异有统计学意义(χ2=41.681,P﹤0.01)。AML组CD117的表达阳性率(58.9%)明显高于对照组(0)及ALL组(8.5%)。CD117/CD34的共表达率ALL组明显低于AML组(4.3%vs45.2%,P﹤0.05)。AML组CD117+患者的CR率为60.5%,CD117-患者为76.7%,两者比较差异无统计学意义(P>0.05);而CD117+/CD34+患者的CR率为54.5%,明显低于CD117-/CD34-患者的CR率(88.2%,P﹤0.05)。结论 CD117可作为辅助诊断AML的髓系标志抗原,CD34+/CD117+可作为进一步排除ALL的指标。CD117+/CD34+可能是AML中一类预后不良的特殊亚型,可以作为AML预后判断的指标之一。

Objective To explore the expression of CD117 in acute leukemia（AL） and its clinical significanc. Method CD117 expression was analysed by flow cytometry with CD45/SSC gating and direct immunofluorescence staining from 73 patients with acute myeloid leukemia （AML） and 47 patients with acute lymphoblastic leukemia （ALL）. Results There was significant difference in the positive rates of CD117 between. control, ALL and AML （？字2=41.681,P0.01）.The CD117 positive rate in AML （58.9%） was significantly higher than those in conthol 0 and ALL （8.5%）. The co-expression rate of CD117/CD34 was significantly lower in ALL than in AML（4.3% vs 45.2%,P0.05）. The CR rates of CD117＋ patients and CD117-patients were 60.5% and 76.7% in AML, respectively. No statistical significant difference can be found （P0.05）. But the CR rate of CD117＋/CD34＋ patients was significantly lower than that of CD117-/CD34-（54.5% vs 88.2%,P0.05）. Conclusions CD117 can be used as myeloid marker for the diagnosis of AML. CD34＋/CD117＋ can be used in the exclusion of ALL. CD117＋/CD34＋ may be a special subtype of poor prognosis and can be used as an indicator of prognosis in AML.